Ashar Bhavesh — SEC Form 4 filings
SEC reporting owner CIK 1849740. 8 Form 4 filings on record with FilingPulse; latest filed 2026-05-07.
Transaction summary — filings shown
Covers all 8 filings on record, filed 2024-02-05 to 2026-05-07. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 2 filings — 9,072 shares, $443,579 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
- Largest priced transaction: sale of 4,834 shares @ $49.32 ($238,435) in SpringWorks Therapeutics, Inc., filed 2024-02-05.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| SpringWorks Therapeutics, Inc. (SWTX) | Chief Commercial Officer | 6 | — | 6 legs · 9,072 sh · $443,579 | 12 |
| Tyra Biosciences, Inc. (TYRA) | Chief Operating Officer | 2 | — | — | 3 |
Form 4 filings — Ashar Bhavesh
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-07 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 15,013 @ $0 · Grant/award (A): 50,295 (derivative) @ $0 | EDGAR |
| 2025-12-01 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Disposition to issuer (D): 62,053 · Disposition to issuer (D): 21,654 (derivative) · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 70,000 (derivative) · Disposition to issuer (D): 75,000 (derivative) · Disposition to issuer (D): 50,615 (derivative) | EDGAR |
| 2025-02-24 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Sale (S): 1,016 @ $61.19 | EDGAR |
| 2025-01-14 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Grant/award (A): 17,323 @ $0 · Grant/award (A): 50,615 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Tax withholding (F): 4,475 @ $38.19 · Tax withholding (F): 3,825 @ $38.19 · Tax withholding (F): 2,284 @ $38.86 | EDGAR |
| 2024-04-03 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Tax withholding (F): 1,824 @ $47.62 | EDGAR |
| 2024-02-05 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Sale (S): 1,089 @ $43.75 · Sale (S): 1,667 @ $44.31 · Sale (S): 378 @ $46.00 · Sale (S): 88 @ $46.37 · Sale (S): 4,834 @ $49.32 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1849740 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →